POTASSIUM CHLORIDE IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE IN PLASTIC CONTAINER (POTASSIUM CHLORIDE IN PLASTIC CONTAINER).
Potassium chloride dissociates to potassium ions, which are essential for maintenance of intracellular tonicity, nerve impulse conduction, muscle contraction, and cardiac function.
| Metabolism | Potassium is not metabolized but is primarily excreted by the kidneys. Excreted mainly as potassium ions in urine. |
| Excretion | Primarily renal (90% excreted unchanged in urine); minor fecal elimination (<10%) via unabsorbed potassium. |
| Half-life | No classical terminal half-life; plasma potassium is rapidly regulated by cellular uptake and renal excretion, with equilibration half-life of ~1-2 hours in normal renal function. |
| Protein binding | Not protein-bound (free ion; negligible binding to albumin). |
| Volume of Distribution | 0.5-0.6 L/kg (total body water); distributes primarily in extracellular fluid (14% of body weight). |
| Bioavailability | Oral: 90-100% (well absorbed from small intestine); IV: 100%. |
| Onset of Action | IV: Immediate (within seconds to minutes); oral: 30-60 minutes. |
| Duration of Action | IV: 2-4 hours (rapid redistribution and excretion); oral: 4-6 hours (sustained-release formulations up to 8-12 hours). |
| Molecular Weight | 74.55 |
10-20 mEq intravenously over 1 hour, not exceeding 10 mEq/hour or 200 mEq per day; oral dosing for hypokalemia: 20-40 mEq 2-4 times daily.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 10-30 mL/min: reduce dose by 50%; GFR <10 mL/min: avoid use or use with extreme caution, maximum 40 mEq/day. |
| Liver impairment | No specific adjustment required; monitor potassium levels closely in severe hepatic impairment due to risk of hyperkalemia. |
| Pediatric use | 0.5-1 mEq/kg/dose intravenously, maximum rate 0.5 mEq/kg/hour; oral: 1-3 mEq/kg/day divided 2-4 times daily. |
| Geriatric use | Initiate at lower end of dosing range; monitor renal function and potassium levels frequently due to age-related decline in renal function. |
| 1st trimester | Potassium chloride is essential for maternal and fetal homeostasis. No teratogenic effects reported. Use only when clearly needed and for correction of hypokalemia. |
| 2nd trimester | Same as t1. Monitor serum potassium levels closely to avoid hyperkalemia, which may affect fetal cardiac function. |
| 3rd trimester | Use with caution. Maternal hyperkalemia may cause fetal bradycardia or arrhythmias. Monitor potassium levels and fetal heart rate if intravenous administration. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE IN PLASTIC CONTAINER (POTASSIUM CHLORIDE IN PLASTIC CONTAINER).
| Placental transfer | Potassium crosses the placenta via active transport and passive diffusion. Fetal serum potassium is maintained within a narrow range (4-5.5 mEq/L) independent of maternal levels, but severe maternal hyperkalemia can increase fetal potassium. |
| Breastfeeding | Potassium chloride is a normal constituent of breast milk. Administration in usual doses is compatible with breastfeeding. No adverse effects reported in infants. However, monitor maternal potassium levels to avoid excessive intake. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride is considered to have low teratogenic risk. No evidence of fetal harm in first trimester. Normal physiological potassium levels are essential for fetal development; both hypo- and hyperkalemia may pose risks. Second and third trimesters: maternal hyperkalemia can affect fetal cardiac function. |
| Fetal Monitoring | Monitor serum potassium levels, renal function, ECG for signs of hyperkalemia, especially in mothers with renal impairment, preeclampsia, or receiving other potassium-altering drugs. Fetal monitoring may be indicated if maternal hyperkalemia is severe. |
| Fertility Effects | No known adverse effects on fertility at therapeutic doses. Hyper- or hypokalemia may impair reproductive function indirectly by affecting cellular processes, but potassium chloride supplementation does not directly alter fertility. |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia. High concentrations may cause cardiac arrest. Do not administer undiluted.
| Serious Effects |
Hyperkalemia (serum potassium >5.5 mEq/L)Severe renal impairment with oliguria or anuriaAddison's diseaseAcute dehydrationHeat crampsConcurrent use of potassium-sparing diuretics (e.g., amiloride, spironolactone, triamterene) without close monitoringCrush syndrome or extensive tissue breakdown
| Precautions | Risk of hyperkalemia, especially in renal impairment. Monitor serum potassium levels. Use with caution in patients with cardiac disease, adrenal insufficiency, or acid-base disorders. Avoid rapid infusion. Do not add to blood products. |
| Food/Dietary | Avoid excessive intake of potassium-rich foods (bananas, oranges, spinach, potatoes, avocados, dried fruits) without medical supervision. Avoid salt substitutes containing potassium chloride. Do not combine with potassium-containing dietary supplements. |
| Clinical Pearls | Do not administer undiluted; must be diluted in compatible IV fluid. Rate of infusion should not exceed 10-20 mmol/h in adults to avoid hyperkalemia. Continuous cardiac monitoring recommended for concentrations >40 mmol/L. Avoid in patients with severe renal impairment or metabolic acidosis. Use with caution in patients receiving potassium-sparing diuretics or ACE inhibitors. |
| Patient Advice | Do not stop taking this medication without consulting your doctor. · Report symptoms of hyperkalemia: muscle weakness, irregular heartbeat, tingling in hands/feet. · Maintain adequate dietary potassium only if instructed by your doctor. · Do not use salt substitutes containing potassium without medical advice. · Report any injection site reactions or signs of phlebitis. |
Loading safety data…